ABI, Zydus Cadila sign Maxisal supply agreement

As per the terms of the agreement, Zydus will market ABI’s dietary supplement Maxisal in India and Nepal.

Maxisal enhances salivary function, promotes oral comfort and helps relieve dry mouth, ABI said.

ABI initially launched Maxisal in the US after clinical studies in subjects with Sjogren’s syndrome (characterised by dry eyes and dry mouth) found that the active ingredient in Maxisal significantly improved mouth comfort and decreased mouth and throat dryness.

Maxisal is marketed in Germany by ABI’s licensee Egofocus OHG, based in Darmstadt.

ABI president and CEO Joseph Cummins said that based on the favorable reception Maxisal has met in the US, they fully expect that it would be successful in India.

Amarillo Biosciences is a US biotechnology firm operating in global partnership with the Hayashibara Group. The company’s primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough and opportunistic infections in patients who are HIV positive.